Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
Type:
Application
Filed:
May 2, 2011
Publication date:
October 27, 2011
Applicant:
Wyeth LLC
Inventors:
Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
Type:
Grant
Filed:
March 9, 2007
Date of Patent:
October 25, 2011
Assignee:
Wyeth LLC
Inventors:
Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil Sreekumar
Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
Type:
Grant
Filed:
May 22, 2009
Date of Patent:
October 18, 2011
Assignee:
Wyeth LLC
Inventors:
Aranapakam Mudumbai Venkatesan, Zecheng Chen, Christoph Martin Dehnhardt, Osvaldo dos Santos, Efren Guillermo Delos Santos, Arie Zask, Jeroen Cunera Verheijen, Joshua Aaron Kaplan, David James Richard, Semiramis Ayral-Kaloustian, Tarek Suhayl Mansour, Ariamala Gopalsamy, Kevin Joseph Curran, Mengxiao Shi
Abstract: Methods and processes for improved recombinant protein production are provided. The methods are useful for production of growth factors, particularly those of the TGF-? superfamily, including bone morphogenetic proteins (BMPs), such as BMP-2. Suitable host cells are cultured in media where iron is present at a concentration of at least 2.25 ?M and if pyridoxal is present, it makes up less than 55% of the molar concentration of vitamin B6 in the media.
Type:
Grant
Filed:
April 16, 2009
Date of Patent:
October 18, 2011
Assignee:
Wyeth LLC
Inventors:
Yen-Tung Luan, Wenge Wang, Gregg Nyberg, Jose Manuel Gomes, Denis Drapeau, Terry Cardoza
Abstract: Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis.
Abstract: ?-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing ?-hemolytic streptococcal infection, and for detecting ?-hemolytic streptococci in a biological sample.
Type:
Application
Filed:
January 24, 2011
Publication date:
October 6, 2011
Applicant:
WYETH LLC
Inventors:
Stephen Bruce Olmsted, Robert John Zagursky, Elliott Bruce Nickbarg, Laurie Anne Winter
Abstract: A polyketide synthase complex composed of polyketide synthase with 15 total modules, a non-ribosomal peptide synthetase with 1 module, and a cytochrome P450 hydroxylase is described. Also provided are novel Streptomyces species and methods of modified Streptomyces species. Further described are novel compounds, 36-ketomeridamycin, C9-deoxomeridamycin, and C9-deoxoprolylmeridamcyin and uses thereof.
Type:
Grant
Filed:
July 25, 2008
Date of Patent:
October 4, 2011
Assignee:
Wyeth LLC
Inventors:
Min He, John Hucul, Bradley Arnold Haltli, Melissa M. Wagenaar, Edmund Idris Graziani, Mia Summers, Kerry Kulowski, Kevin Pong, Xidong Feng
Abstract: Parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl) -2-methylpropionic acid (CCI-779) are provided. One parenteral formulation contains CCI-779, an alcoholic co-solvent, and an antioxidant. Another parenteral formulation contains CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant. Processes for preparing parenteral CCI-779 formulations using a co-solvent concentrate are also provided.
Type:
Grant
Filed:
July 25, 2003
Date of Patent:
September 27, 2011
Assignee:
Wyeth LLC
Inventors:
Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
Abstract: Child-resistant bulk dose dispensing packaging unit, and a method for opening the packaging unit, including a container and a lid engaged with the container. The container includes a reservoir, an aperture at a top end of the reservoir, and a protrusion extending from a surface of the container. The lid engages with the container and slides between a closed position and an open position. The lid includes a top wall, a side wall extending down from an outer edge of the top wall, and a post configured to engage the protrusion at a first position when the lid is closed so as to keep the lid closed. At least a portion of the post extends substantially parallel to the side wall at a distance from the side wall. Pressing the side wall inward places the post at a second position, wherein at the second position the post is disengaged from the protrusion.
Abstract: The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A?. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.
Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
Type:
Grant
Filed:
October 15, 2008
Date of Patent:
September 20, 2011
Assignee:
Wyeth LLC
Inventors:
Qinghong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
Abstract: The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans.
Type:
Application
Filed:
February 9, 2011
Publication date:
September 15, 2011
Applicant:
Wyeth LLC
Inventors:
William Bubnis, Richard Cotter, Paul W. Herman, Judith Moreines, Scott W. Poxon, Bruce W. Sutton, Jeffrey V. Vernon, Denise L. Walters, Michael G. Williams, Neil Wittenberg
Abstract: Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
Type:
Application
Filed:
May 12, 2011
Publication date:
September 1, 2011
Applicant:
Wyeth LLC
Inventors:
Marc Sadler Tesconi, Mannching Sherry Ku, Yan Xu
Abstract: The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-23
Type:
Application
Filed:
March 15, 2011
Publication date:
September 1, 2011
Applicant:
Wyeth LLC
Inventors:
Spencer C. LIANG, Lynette A. Fouser, Margot O'Toole
Abstract: Methods for preparing cyclic carbamates and thiocarbamates containing cyanopyrrole moieties and of the formula are provided. Z are the same or different and are H, optionally substituted C1 to C6 alkyl, or CORA; RA is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl; Q are the same or different and are H, OH, NH2, CN, halogen, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C1 to C6 alkynyl, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 aminoalkyl, or CORB; and RB is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl.
Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.
Type:
Grant
Filed:
September 23, 2009
Date of Patent:
August 23, 2011
Assignees:
Wyeth LLC, Etex Corporation
Inventors:
Rebecca Li, Howard Seeherman, Aliassghar Tofighi
Abstract: The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of A? or an agent that can induce such an antibody.
Abstract: The present invention is directed to a thermal covering that delivers consistent therapy to a portion of a user's hand-wrist area, is easy to use and apply to the body, and is securely positionable on the body. The thermal covering can be entirely disposable after one use. The thermal covering can also have a disposable component and a reusable component that can be packaged individually together as a kit.
Type:
Grant
Filed:
September 7, 2007
Date of Patent:
August 23, 2011
Assignee:
Wyeth LLC
Inventors:
Donald Stephen Bretl, Mary Elaine Freeland, Kyle William Harris, Richard W. Pack, Angela Marie Reed
Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.
Abstract: The present invention relates to modulators of metalloproteinase activity.
Type:
Grant
Filed:
May 14, 2009
Date of Patent:
August 16, 2011
Assignee:
Wyeth LLC
Inventors:
Phaik-Eng Sum, Jerauld Stanley Skotnicki, Steve Yik-Kai Tam, Tarek Suhayl Mansour, David Brian How, Joshua James Sabatini, Jason Shaoyun Xiang, Eric Feyfant